Journal of Clinical Epidemiology
Volume 50, Issue 2 , Pages 185-193 , February 1997

Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias

  • Mark A. Hlatky

      Affiliations

    • Corresponding Author InformationAddress for correspondence: and reprints: Mark Hlatky, M.D., Stanford University School of Medicine, HRP Redwood Building, Room 150, Stanford, CA 94305-5092.
    • Department of Health Research and Policy and Department of Medicine, Stanford University School of Medicine, Stanford, California 94305-5092 U.S.A.
    • ,
  • Derek B. Boothroyd

      Affiliations

    • Department of Health Research and Policy and Department of Medicine, Stanford University School of Medicine, Stanford, California 94305-5092 U.S.A.
    • ,
  • Iain M. Johnstone

      Affiliations

    • Department of Health Research and Policy and Department of Medicine, Stanford University School of Medicine, Stanford, California 94305-5092 U.S.A.
    • ,
  • Frank I. Marcus

      Affiliations

    • Department of Medicine, University of Arizona School of Medicine, Tucson, Arizona 85724 U.S.A.
    • ,
  • Elizabeth Hahn

      Affiliations

    • Department of Medicine, University of Arizona School of Medicine, Tucson, Arizona 85724 U.S.A.
    • ,
  • Vernon Hartz

      Affiliations

    • Department of Medicine, University of Arizona School of Medicine, Tucson, Arizona 85724 U.S.A.
    • ,
  • Jay W. Mason

      Affiliations

    • Department of Medicine, University of Utah School of Medicine, Salt lake City, Utah 84132 U.S.A.

,Accepted 4 September 1996.

References 

  1. Detsky AS. Guidelines for economic analysis of pharmaceutical products. A draft document for Ontario and Canada. PharmacoEconomics. 1993;3:354–361
  2. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomized control trials. Medical Care. 1992;30:231–243
  3. ESVEM Investigators . The ESVEM trial. Electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular arrhythmias. Circulation. 1989;79:1354–1360
  4. ESVEM Investigators . Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiologic Study Versus Electrocardiographic Monitoring trial. Circulation. 1993;87:323–329
  5. Mason JW, ESVEM Investigators . A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med. 1993;329:445–451
  6. Mason JW, ESVEM Investigators . A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 1993;329:452–458
  7. Omoigui NA, Marcus FI, Mason JW, Hahn EA, Hartz VL, Hlatky MA. Cost of initial therapy in the Electrophysiologic Study Versus ECG Monitoring trial (ESVEM). Circulation. 1995;91:1070–1076
  8. Mitchell LB, Duff HJ, Manyari DE, Wyse DG. A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med. 1987;317:1681–1687
  9. Mitchell LB, Duff HJ, Miller CE, Eliasoph HP, Wyse DG. Drug therapy of ventricular tachycardia: A cost comparison of randomized noninvasive and invasive approaches. Can J Cardiol. 1992;8:487–494
  10. In: Health United States 1992 and Healthy People 2000 Review. 2nd Ed.. DHHS Publication Number (PHS) 93-1232. Hyattsville, MD: National Center for Health Statistics; 1993;p. 164
  11. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716–721
  12. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990;113:147–154
  13. Drummond MF, Stoddart GL, Torrance GW. In: 2nd Ed.. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1987;
  14. Keeler E, Cretin S. Discounting of life savings and other nonmonetary effects. Management Science. 1983;29:300–306
  15. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In:  Gold MR,  Siegel JE,  Russell LB,  Weinstein MC editor. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996;p. 214–235
  16. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1995;49:1–13
  17. Efron B, Tibshirani R. Statistical data analysis in the computer age. Science. 1991;253:390–395
  18. Efron B, Tibshirani R. In: 2nd Ed.. An Introduction to the Bootstrap. London & New York: Chapman and Hall; 1993;
  19. Task Force on Principles for Economic Analysis of Health Care Technology . Economic analysis of health care technology. A report on principles. Ann Intern Med. 1995;123:61–70
  20. Dudley RA, Harrell FE, Smith LR, et al.  Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol. 1993;46:261–271
  21. Roper WL, Winkenwerder W, Hackbarth GM, Krakauer H. Effetiveness in health care. An initiative to improve medical practice. N Engl J Med. 1988;319:1197–1202
  22. Roos NP, Wennberg JE, Malenka DJ, et al.  Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989;320:1120–1124
  23. Andersen C. Measuring what works in health care. Science. 1994;263:1080–1082
  24. CASADE Investigators . Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. 1993;72:280–287
  25. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al.  Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992;20:1056–1062
  26. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Pilot Study. Circulation. 1991;84:550–557
  27. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 1900;81:91–100
  28. O'Donoghue S, Platia EV, Brooks-Robinson S, Mispireta L. Automatic implantable cardioverter-defibrillator: Is early implantation cost-effective?. J Am Coll Cardiol. 1990;16:1258–1266
  29. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NAM, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19:1323–1334
  30. O'Nunain S, Ruskin J. Cardiac arrest. Lancet. 1993;341:1641–1647

☆ Presented in part at the meeting of the American Federation for Clinical Research, May 1993. Refer to [5] which has an Appendix listing the ESVEM Investigators.

☆☆ Supported by a grant from Bristol-Meyers Squibb Company, Princeton, New Jersey, and Grant HL-34071 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. Additional support from Knoll Pharmaceuticals, Whippany, New Jersey; Boehringer-Ingleheim Corporation, Ridgefield, Connecticut; Ciba-Geigy Corporation, Summit, New Jersey; Grant RR-00064 from the National Center for Research Resources, Bethesda, Maryland; and the Robert Wood Johnson Foundation, Princeton, New Jersey.

PII: S0895-4356(96)00331-9

Journal of Clinical Epidemiology
Volume 50, Issue 2 , Pages 185-193 , February 1997

Article Tools